Canada· CA-DIN-02527618
VABYSMO
A faricimab product containing faricimab, registered in Canada by HOFFMANN-LA ROCHE LIMITED. The same ATC class is registered in 14 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Faricimab is registered in 14 of 19 countries.
Countries holding a registration under ATC S01LA09 (faricimab), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 9 of them publish a price we can compare per daily dose
Faricimab · ATC S01LA09
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- FARICIMAB
- Manufacturer
- HOFFMANN-LA ROCHE LIMITED
- Country
- Canada (CA)
- ATC code
- S01LA09
- ATC class
- Faricimab
- Defined daily dose
- 0.0357 DE, IVT
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Faricimab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainVABYSMO 120 MG/ML SOLUCION INYECTABLERoche Registration Gmbh
- FinlandVabysmoAbacus Medicine A/S
- CzechiaVABYSMORoche Registration GmbH, Grenzach-Wyhlen
- BelgiumVabysmo 120 mg/mlRoche Registration
- SwitzerlandVabysmo 6 mg/0,05 ml, InjektionslösungRoche Pharma (Schweiz) AG
- IcelandVabysmoRoche Registration GmbH*
- Japanファリシマブ（遺伝子組換え）中外製薬
- NorwayVabysmoRoche Registration GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Vabysmo
- Liechtenstein · Vabysmo
- Norway · Vabysmo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bb18a68e-e1a7-4a81-bc41-7ef32127bac1 GET /v1/drugs/bb18a68e-e1a7-4a81-bc41-7ef32127bac1?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02527618",
"form": "SOLUTION",
"class": "Human",
"routes": [
"INTRAVITREAL"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "S01LA09",
"schedule": [
"Schedule D",
"Prescription"
],
"drug_code": "101666",
"strengths": [
"6 MG"
],
"ahfs_class": null,
"substances": [
"FARICIMAB"
],
"product_categorization": null
}See everything about faricimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.